Glucotrack（GCTK）宣布1:15反向拆股以维持纳斯达克上市合规，8月31日生效

----- 0001493152-26-040332.txt -----
0001493152-26-040332.txt : 20260827
0001493152-26-040332.hdr.sgml : 20260827
20260827084431
ACCESSION NUMBER: 0001493152-26-040332
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 12
CONFORMED PERIOD OF REPORT: 20260827
ITEM INFORMATION: Regulation FD Disclosure
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260827
DATE AS OF CHANGE: 20260827
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Glucotrack, Inc.
CENTRAL INDEX KEY: 0001506983
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
EIN: 980668934
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41141
FILM NUMBER: 261325377
BUSINESS ADDRESS:
STREET 1: 301 RT 17 NORTH
STREET 2: SUITE 800
CITY: RUTHERFORD
STATE: NJ
ZIP: 07070
BUSINESS PHONE: 972 (8) 675-7878
MAIL ADDRESS:
STREET 1: 301 RT 17 NORTH
STREET 2: SUITE 800
CITY: RUTHERFORD
STATE: NJ
ZIP: 07070
FORMER COMPANY:
FORMER CONFORMED NAME: GlucoTrack, Inc.
DATE OF NAME CHANGE: 20220328
FORMER COMPANY:
FORMER CONFORMED NAME: Integrity Applications, Inc.
DATE OF NAME CHANGE: 20101203
8-K
1
form8-k.htm
8-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
August 27, 2026
GLUCOTRACK,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
001-41141
98-0668934
(State
or Other Jurisdiction
(Commission
(IRS
Employer
of
Incorporation)
File
Number)
Identification
No.)
301
Rte. 17 North
,
Ste. 800
,
Rutherford
,
NJ
07070
(Address
of principal executive offices)
(Zip
Code)
Registrant’s
telephone number, including area code:
(201)
842-7715
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock, par value $0.001 per share
GCTK
The
Nasdaq Stock Market LLC
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure
On
August 27, 2026, Glucotrack, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”),
which announced a 1-for-15 reverse stock split of the Company’s common stock, par value $0.001 per share, effective with the opening
of trading on August 31, 2026. The Press Release is furnished as Exhibit 99.1.
The
information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the
Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates
it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
Exhibit
No.
Description
99.1
Press Release dated August 27, 2026
104
Cover
Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
August 27, 2026
GLUCOTRACK,
INC.
By:
/s/
Erik Emerson
Name:
Erik
Emerson
Title:
Chief
Executive Officer
EX-99.1
2
ex99-1.htm
EX-99.1
Exhibit
99.1
Glucotrack,
Inc. Announces Reverse Stock Split
1-for-15
reverse stock split to become effective as of the opening of trading on August 31, 2026
RUTHERFORD,
N.J., and LA JOLLA, C.A., August 27, 2026 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”),
a healthcare technology and biopharmaceutical company operating Lōkahi Therapeutics™,
today
announced that it will effect a 1-for-15 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common
stock par value $0.001 per share (the “Common Stock”), effective with the opening of trading on Monday, August 31, 2026.
Glucotrack’s
Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK.” The new
CUSIP number for the Common Stock following the Reverse Stock Split will be 45824Q887.
The
material effects of the Reverse Stock Split will be:
●
Every
15 shares of Glucotrack’s issued and outstanding Common Stock will be combined into
one (1) share of Common Stock.
●
The
number of total outstanding shares of Common Stock will be proportionally reduced from 11,972,157
shares to approximately 798,144 shares.
●
The
ownership percentage of each Glucotrack stockholder will remain unchanged, other than as
a result of fractional shares. No fractional shares of Common Stock will be issued in connection
with the Reverse Stock Split. Instead, stockholders who otherwise would be entitled to receive
fractional shares because they hold a number of shares not evenly divisible by the reverse
stock split ratio will automatically be entitled to receive an additional fraction of a share
of Common Stock to round up to the next whole share.
At
the annual meeting of stockholders held on August 18, 2026, the stockholders of the Company approved a proposal to authorize the Company’s
management to file one or more certificates of amendment to the Company’s certificate of incorporation to effect one or more reverse
stock splits at an aggregate ratio not to exceed 1-for-30, as determined by the Company’s management in its sole discretion.
Among
other considerations, the Reverse Stock Split is intended to bring Glucotrack into compliance with the $1.00 minimum bid price requirement
for maintaining the listing of its Common Stock on the Nasdaq Capital Market and to make the prevailing prices of its Common Stock more
attractive to a broader group of institutional investors. Following the Reverse Stock Split, the Company must maintain a closing bid
price of at least $1.00 for each trading day through November 9, 2026. In addition, if the Company becomes deficient with any other Nasdaq
listing requirement during the term of this exception, it will have seven (7) calendar days to present a plan to regain compliance to
the Nasdaq Hearings Panel (the “Panel”). The Panel will then determine whether to grant the Company an additional exception
period to cure the deficiency or to delist the Company. Accordingly, if the Company fails to maintain compliance with Nasdaq listing
requirements prior to November 9, 2026, its securities may be delisted at Nasdaq’s discretion.
The
combination of, and reduction in, the number of issued shares of Common Stock as a result of the Reverse Stock Split will occur automatically
at the opening of trading on August 31, 2026, without any additional action on the part of Glucotrack’s stockholders. Glucotrack’s
transfer agent, VStock Transfer, LLC, is acting as the exchange agent for the Reverse Stock Split and will send each stockholder a transaction
statement indicating the number of shares of Common Stock the stockholder holds after the Reverse Stock Split. Stockholders owning shares
via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split, subject
to such broker’s particular processes. Such stockholders will not be required to take any action in connection with the Reverse
Stock Split.
Additional
information regarding the Reverse Stock Split can be found in the Company’s Definitive Proxy Statement on Schedule 14A, filed with
the U.S. Securities and Exchange Commission on July 17, 2026. A link to this document is available at
https://www.sec.gov
.
About
Glucotrack, Inc.
Glucotrack,
Inc. (NASDAQ: GCTK) operates Lōkahi Therapeutics™, a biopharmaceutical platform focused on advancing innovative therapeutic
opportunities through disciplined evaluation, strategic development, and collaborative discovery. Through its ai² platform, Lōkahi
Therapeutics™ seeks to identify, evaluate, and advance differentiated healthcare and life sciences opportunities. For more information,
please visit
www.lokahithera.com
. In addition, through its subsidiary Glucotrack Technologies, Inc., the Company is focused on
the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous
blood glucose monitoring system. The Glucotrack CBGM is an investigational device and is limited by federal (or United States) law to
investigational use. For more information, please visit
www.glucotrack.com
. Information on the Company’s website does not
constitute a part of and is not incorporated by reference into this press release.
Forward-Looking
Statements
This
news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements
contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting
the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “intend”,
“plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based
on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate
only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking
statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results
anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects
on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results
and could cause such results to differ materially from any forward-looking statements that may be made in this news release. These factors
include, but are not limited to: the anticipated benefits of the Reverse Stock Split, including the effect the Reverse Stock Split will
have on the Company’s ability to regain and maintain compliance with the Nasdaq listing standards; the Company’s ability
to maintain a closing bid price of at least $1.00 for each trading day through November 9, 2026; the risk that the Company’s securities
may be delisted from Nasdaq if it fails to maintain compliance with applicable listing requirements; the ability to make the Company’s
Common Stock more attractive to institutional investors; the ability of Glucotrack to raise additional capital to finance its operations
(whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt
(and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability
to hire and retain qualified personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities
and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March
30, 2026.
Contacts:
Investor Relations:
ir@lokahithera.com
EX-101.SCH
3
gctk-20260827.xsd
XBRL SCHEMA FILE
00000001 - Document - Cover
link:presentationLink
link:calculationLink
link:definitionLink
EX-101.LAB
4
gctk-20260827_lab.xml
XBRL LABEL FILE
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
EX-101.PRE
5
gctk-20260827_pre.xml
XBRL PRESENTATION FILE
XML
7
R1.htm
IDEA: XBRL DOCUMENT
Cover
Aug. 27, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 27, 2026
Entity File Number
001-41141
Entity Registrant Name
GLUCOTRACK,
INC.
Entity Central Index Key
0001506983
Entity Tax Identification Number
98-0668934
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
301
Rte. 17 North
Entity Address, Address Line Two
Ste. 800
Entity Address, City or Town
Rutherford
Entity Address, State or Province
NJ
Entity Address, Postal Zip Code
07070
City Area Code
(201)
Local Phone Number
842-7715
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common
Stock, par value $0.001 per share
Trading Symbol
GCTK
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
XML
8
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
9
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
11
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
23
1
false
0
0
false
0
false
false
R1.htm
00000001 - Document - Cover
Sheet
http://glucotrack.com/role/Cover
Cover
Cover
1
false
false
All Reports
Book
All Reports
form8-k.htm
gctk-20260827.xsd
gctk-20260827_lab.xml
gctk-20260827_pre.xml
http://xbrl.sec.gov/dei/2026
true
false
JSON
13
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"form8-k.htm": {
"nsprefix": "GCTK",
"nsuri": "http://glucotrack.com/20260827",
"dts": {
"inline": {
"local": [
"form8-k.htm"
]
},
"schema": {
"local": [
"gctk-20260827.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
"https://xbrl.sec.gov/country/2026/country-2026.xsd",
"https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
"https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
]
},
"labelLink": {
"local": [
"gctk-20260827_lab.xml"
]
},
"presentationLink": {
"local": [
"gctk-20260827_pre.xml"
]
}
},
"keyStandard": 23,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 2,
"http://xbrl.sec.gov/dei/2026": 2
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 59,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2026": 23
},
"report": {
"R1": {
"role": "http://glucotrack.com/role/Cover",
"longName": "00000001 - Document - Cover",
"shortName": "Cover",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "AsOf2026-08-27",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"b",
"span",
"p",
"body",
"html"
],
"reportCount": 1,
"baseRef": "form8-k.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "AsOf2026-08-27",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"b",
"span",
"p",
"body",
"html"
],
"reportCount": 1,
"baseRef": "form8-k.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentDescription": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AmendmentDescription",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Description",
"documentation": "Description of changes contained within amended document."
}
}
},
"auth_ref": []
},
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AmendmentFlag",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_AnnualInformationForm": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AnnualInformationForm",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Annual Information Form",
"documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_AuditedAnnualFinancialStatements": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AuditedAnnualFinancialStatements",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Audited Annual Financial Statements",
"documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CityAreaCode",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CountryRegion": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CountryRegion",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Country Region",
"documentation": "Region code of country"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_CurrentFiscalYearEndDate": {
"xbrltype": "gMonthDayItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CurrentFiscalYearEndDate",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Current Fiscal Year End Date",
"documentation": "End date of current fiscal year in the format --MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentAccountingStandard": {
"xbrltype": "accountingStandardItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentAccountingStandard",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Accounting Standard",
"documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentAnnualReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentAnnualReport",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Annual Report",
"documentation": "Boolean flag that is true only for a form used as an annual report."
}
}
},
"auth_ref": [
"r11",
"r13",
"r14"
]
},
"dei_DocumentFiscalPeriodFocus": {
"xbrltype": "fiscalPeriodItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentFiscalPeriodFocus",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Period Focus",
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
}
}
},
"auth_ref": []
},
"dei_DocumentFiscalYearFocus": {
"xbrltype": "gYearItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentFiscalYearFocus",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Year Focus",
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodStartDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentPeriodStartDate",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period Start Date",
"documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
}
}
},
"auth_ref": []
},
"dei_DocumentQuarterlyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentQuarterlyReport",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Quarterly Report",
"documentation": "Boolean flag that is true only for a form used as an quarterly report."
}
}
},
"auth_ref": [
"r12"
]
},
"dei_DocumentRegistrationStatement": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentRegistrationStatement",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Registration Statement",
"documentation": "Boolean flag that is true only for a form used as a registration statement."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_DocumentShellCompanyEventDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentShellCompanyEventDate",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Shell Company Event Date",
"documentation": "Date of event requiring a shell company report."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentShellCompanyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentShellCompanyReport",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Shell Company Report",
"documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentTransitionReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentTransitionReport",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Transition Report",
"documentation": "Boolean flag that is true only for a form used as a transition report."
}
}
},
"auth_ref": [
"r15"
]
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentType",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_DocumentsIncorporatedByReferenceTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentsIncorporatedByReferenceTextBlock",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Documents Incorporated by Reference [Text Block]",
"documentation": "Documents incorporated by reference."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine2": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine2",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Two",
"documentation": "Address Line 2 such as Street or Suite number"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine3": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine3",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Three",
"documentation": "Address Line 3 such as an Office Park"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCountry": {
"xbrltype": "countryCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressCountry",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Country",
"documentation": "ISO 3166-1 alpha-2 country code."
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityBankruptcyProceedingsReportingCurrent": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityBankruptcyProceedingsReportingCurrent",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Bankruptcy Proceedings, Reporting Current",
"documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
}
}
},
"auth_ref": [
"r6"
]
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityCommonStockSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCommonStockSharesOutstanding",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Common Stock, Shares Outstanding",
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
}
}
},
"auth_ref": []
},
"dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCurrentReportingStatus",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": []
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityExTransitionPeriod": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityExTransitionPeriod",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Elected Not To Use the Extended Transition Period",
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
}
}
},
"auth_ref": [
"r19"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityFileNumber",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityFilerCategory": {
"xbrltype": "filerCategoryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityFilerCategory",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Filer Category",
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityInteractiveDataCurrent": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityInteractiveDataCurrent",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Interactive Data Current",
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
}
}
},
"auth_ref": [
"r16"
]
},
"dei_EntityPrimarySicNumber": {
"xbrltype": "sicNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityPrimarySicNumber",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Primary SIC Number",
"documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_EntityPublicFloat": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityPublicFloat",
"crdr": "credit",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Public Float",
"documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityRegistrantName",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityShellCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityShellCompany",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Shell Company",
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntitySmallBusiness": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntitySmallBusiness",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Small Business",
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityVoluntaryFilers": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityVoluntaryFilers",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Voluntary Filers",
"documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
}
}
},
"auth_ref": []
},
"dei_EntityWellKnownSeasonedIssuer": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityWellKnownSeasonedIssuer",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Well-known Seasoned Issuer",
"documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
}
}
},
"auth_ref": [
"r17"
]
},
"dei_Extension": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Extension",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Extension",
"documentation": "Extension number for local phone number."
}
}
},
"auth_ref": []
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "LocalPhoneNumber",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_NoTradingSymbolFlag": {
"xbrltype": "trueItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "NoTradingSymbolFlag",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "No Trading Symbol Flag",
"documentation": "Boolean flag that is true only for a security having no trading symbol."
}
}
},
"auth_ref": []
},
"dei_OtherReportingStandardItemNumber": {
"xbrltype": "otherReportingStandardItemNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "OtherReportingStandardItemNumber",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Other Reporting Standard Item Number",
"documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r7"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r9"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Security12bTitle",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_Security12gTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Security12gTitle",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(g) Security",
"documentation": "Title of a 12(g) registered security."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SecurityExchangeName",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_SecurityReportingObligation": {
"xbrltype": "securityReportingObligationItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SecurityReportingObligation",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Security Reporting Obligation",
"documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
}
}
},
"auth_ref": [
"r10"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SolicitingMaterial",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r8"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "TradingSymbol",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "WrittenCommunications",
"presentation": [
"http://glucotrack.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r18"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-23"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "g"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12, 13, 15d"
},
"r7": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r8": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r9": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r10": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "15",
"Subsection": "d"
},
"r11": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-K",
"Number": "249",
"Section": "310"
},
"r12": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-Q",
"Number": "240",
"Section": "308",
"Subsection": "a"
},
"r13": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Number": "249",
"Section": "220",
"Subsection": "f"
},
"r14": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Number": "249",
"Section": "240",
"Subsection": "f"
},
"r15": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Section": "13",
"Subsection": "a-1"
},
"r16": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-T",
"Number": "232",
"Section": "405"
},
"r17": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "405"
},
"r18": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
},
"r19": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "7A",
"Section": "B",
"Subsection": "2"
}
}
}
ZIP
14
0001493152-26-040332-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001493152-26-040332-xbrl.zip
M4$L#!!0 ( (YE&UV4B]*4 Q '!/ * 97@Y.2TQ+FAT;>U<;5/;
MQA;^[AG_A[UI;X;,&(/ST@1PF>L :6EI0@/IG7Y<2VM[BZ15M"L[[J^_SSF[
MDF5C:+A#F9*0F218EG;/ZW/>5O1_//_E9+_=ZO]X-#C$_X+^],^/ST^.]OM;
M_G]\NQ6^[K]^=_B[.#O__>3H^T
C1(SR(1T]O^MR>2&4QUMFNH%OKOWO"J4]N4R9ZC*\BE3E5/-KOOWGW]KRY
MP^9(ICJ9[_[5'GROU7\J3]*C_
GV^ENO]^^&E?NMB-NF?D\,970Q+DR9Q9N124RQ*V83[12KZ(>D
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M>3^W\W1HDLK6"!RZ%1+ .T6F9J#BP]GQJ
#P\/CM#]\_VG[$G\].!P?5Y[#_3,=N0NMM_]MO
A<
GUF]VOGNYL]#K_TO@W^R(1]#*/'15/O,/TA;.'-A?+T>2JQ*2R_$%$(TL
M9:@SW*TS9VY&ALF0N_2>A"P&I#0WZ"[)?>O\/?U#+G6[J-&%T3P@QP-R?(W(
MP2'\)@X;DCH*\H;2QB8X+ !E+4SDA
MU=EX^
M[?1>O+P9.6%+Y+8RQ_J?-*4C6/SESJM.[_GS\/T=
WK($N$C&
M 6RUGF%!!A''.K!1<4342D_O#4UV1?&T$X&:*'/NK'#KXY,CE8!IWN KC3KW
MGZ^!:[=(H3++2MA.JI0+;=(E[YLHN,%B;-)[Y1NE'=\F:]X96B*A-^Y3E2E5
M5SXGLMB$,IC234P!.IHW+UI[H!PPF<+6Z>:13A173Z80J4'M%%%D',$GG(
8]E<"
M5OD4*7#J>^7/MCLTA(J54T7*%6- AU7:&KP"4FD32VX5:QL5B@A\: ;>&[X&
M ,UQN^4#-:*CU;'R5F8[5W8*M:5F BS8@_JP( =L9 ;4:>!94:)E%C5F&M_V
MNMO; L:ETS(50QW#Q71$IONQU 6;5+M%+6E*)!S^5CWH1-O*R\G>EL#^VHXY
MM4A 3"HOO./F\!*I$UJ+M[9KER1_:K>D
E^#32$IV2"6Y]TI0Y
6("
MMNU6I8:&OD1<%A6C!!P>3F$AA"UYV"XTER<2HK24A(B-ET\$,@38D"R(
;(6$I6ZD9@V[@588-+"H+;V"5#*,YSUX-+I#4FNMU
MQ2 "G)/2DODE98Q@GM;;;#"(54\*K =ET F#6AN6K-KONVH"'8_4"I2"$T4P
MSNF9IX_BG1/57"D _1T@^@-&?V8%Y]NX,J3)_O@ -VGXBLX\HBRR_E#S7%$9
M(
H!("H#WARURK^L?J:>@Z69#
M61Z J-@C;[,"EH))D*&XM [)5DB18DKC*HR\5)==JEV6\U.NYT#VR*DK:>OZ
M#W5".\L6#;]V:ZJE#UX7)(>AS"Y@*P4I"-QZ?,\,@:!JH#0NZT(@^V5=V96J
M3L9D_U5)-THH%;TRTMER^ =N@(X,?H;8/"FU
(N9KORF
DA XM0EBJI10.D[7_8GSB7V]VMK=ELUD4,[X[-M+_U8?^K,>!_;6Z*-QHU
M_2Z2N+':P^,?2V19])C8W RGUON'Q[]51*PTN[_C\WG(NE117WN=4+72 [\H
M8'5,7>^;-.7#:A!$(G,+2JJ?ZJ;SHE^_?#YTT5Q?TS)?%GVB1OS$X9I1P$)8
MJSVL_A8DL48HPT+)B\VA@O^ FIPEV1P2?,?DG2[+D$UCL=?I\NH-S6R1:KPV
MO@A3_%J
J_WA\,D4BV6ZLG8N_N>/S?PU:EF#OFXDZ,[O*;#AMO!V>'
M@U^KX\O^.#'6_,O3Q'+-H>0\D8[R 6P
G*C%YRE4&A7H&_2&W
M9J>^"6KHP \U'/R:W(75CVV9/]VKB>TT>6VWUC"+.D-=<"- QS1"&
>- -]V5Z!$*"FY)4+719)L:5:%YW$BIH*2<&DU*T)2(
MLP_*.A)#I+(,NRA&.?M8[BJY!L-(^JV.M2SFS<;@>77 7).]D"DL-\*0^"R4
MZ+.K6%D8;&>=W--4%9&&0?]9E<4H#W#7XAP[J99JNEP9L.1K 1 U5([VUUF4
ME)PZ2I&8;+S)_2N=4O/)<>X5CN>:$F74,#$F%F-B!J)!O::=X
L??N%,+@N=03V6H>X%+]33(RYP0Z)3[7RW?:2H^YJ(#=#\(>.KG(C:
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M=BM
KOLRHOABV5
!G(@7/T51ZZHFL1_,Q3\$S
&Q* A357<,$B(%%W[&-@GM?7@>G;'P_%IZZ:[R!MZB(>SJJ%6A*!^C_*WH
ML!1HO$7)H*-GP]%2?TNGWF>^W'@6WH=4S /IT.?A3)A&GOY%%C;
\B(:>1'0&,*/QB3_GS%FEG$
M99D0G72XRQ_"8@ )W_+\C[-S4;V) P'PF=HU%M>T:B8Q@-Z2UIL 6OE2()R2
M0\IH86K#<@&L57[IS*Y7:E.) ,21OO:]H&:>S,KQDKEN9-1NL2JOR"7E4#,"
M+\:[),(KIYV-86\U?N8SS1"
K'&A*J.Y
MO @W+1I^--&AG5 HMLM%J($B+8W;DKV:X(;ZV3LJ8$4M'V%_GPZN(Y,/YMB%
MWZ^,5CS8KIFM-#&**!_XLX'O%4$[X= ;2E-[VYL_UR/>N9)P=
';SXX.^/5K6423=HN.RMW]:]?WO "ZJU^L
.0Z" \R4>@&_OA>([8Z+_85\7_UG3\5QAY3X9U/T]
MP77-[/?IGGCG:])=<4)IW,,H^-I1\-\^K+T/%GOGKK9%OS'/_PH]^DU[_P-0
M2P,$% @ CF4;75#=[A+A$@ TYL L !F;W)M."UK+FAT;>T=:W?:
M.O([OT++[MV;G :PS9LD["$\4IH'N9!'VR\Y?@CLQ-BN+0?HK]^1;(,-)DU2
MDA!*[VT3T$B:&8U&,Z.1=/"_\5!'#]AV--,X_)M/
E4U#)UK4(*/TFZ"2;66@:2I59A3!P
M(>,51D!)+&C> R4!J.:8.8$O/H:'!S&M,%X&RU.<@4+\]:A[.@,G\? ST RQ
M1F ^_;*>4RO)!.PN#$Z64%DNB
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M7]0=_,*6F@8,PZ0.3=FBWC84/#[!DUL.M%.>*Y1+V:
(
;W90$C364!!5C1;=(0":[.L _:F97-UP)165(G*)E#
M*=Q[\)W/O@A+74/S^ F3:YZ)0RPZKHVK_B2L $C05% 4:9^V%=^X-Y^7M>\3
MSV!>V,%,:
5/>UWD'&:A;3202!]9S->L^&HKV0#,J"$#WD24J
MU!+W/U$13(FZ-H!B&68.MO>1!$OSP 9+1DG)IF[:%312-0):^+__Y@O<_D'&
MJKXO'CX&H26LZ^HX=2$.V.H=7D=&FD)4BAWW5S)2()DV,#9%3*N"CG3H">6
M ,?4-05Z]@HEDQ!S&)3SLW)*
04:"@:#-
M5S>1UEZS?M5M7[:;O43MO(&:7^N?:^?'353OG)VU>[UVY_R)#! ^& ,$GP$W
MHJ,"'L0T]A*-=#V-!"Z?*_^2Z#=54JN@EPMKEXT5YU:G>Y;P6J3F _4]RMP1
M
+L-L\O$]WF1:=[N:$#"'1>N+;CB@9)$!/ 9!J 0WP6
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M%!
EIW<2/ITYX5_EJI732G;4H1;=,V9-.&]9/MUO8(K#QU;SNS;BI+E(_Y
M\_QD_/DT.[H67KI"THUD&FLGV++-!SK!%I9(85$[/8HKF M8%T>PV/YJI23*
MPKBN9-Q6.VQS
#[';\7HXXA1+B)&E^*X[>\4RDQ7/"93ME3X8?X\O2R2EP>2^)BM
MWB5()*OE4HHK%$K,'_VEA,$_]NLN:;\SO"LUMIA"9]B9-NH0%=OH"WCSCJ*Q
M0,9KS;NWG6SK@NE.W1P.-
PRWYM#2S0FV_\S9;/899A&+;?
OL;YW]9QO&A<*K&L;U
MB&%<4Q0;.X[_XU0S,!]O%!\7R-&7>T5SSG(O-XKSBT9Q# +):I;C&>N[!*<1
M7X1Y9A-UB6V\MQ#B_Q6%0CR%^0=#,5N]EBH_+\P?H;#P% J%9+5'*2MQW).)
MRL8158=?._:E.3+B2
K79?:YWV8($\FJ15'
M$K/Y._:%;3YHAKPDWG3V3[9P6OOV?71\_W*Z2DOIFL,A63W_LG7]/X[KGX^3
MJPO3(:+^7;.61S&+%\/:Z,9JGG1++Y>J\E*IBF"0K')%^&_K[X<=)9]1GL??
M1Y8-LT^S1!WA,99=HCW031
;#1_
MCOKU;]?&,W=_PGI3B.0_A/L$Z10X?G>)IEQ N^BC?6J"VKN@9#\6ZJV5.A?V
M5?_D<^
::V@53MM$P;1-+/:K#9KBRV
MD>BMQJ N^LC+G(-UB]K#2!>=(,?J3\EM>#W"[ER':/W)FU!65[%\GP!'#8F6
M99M@8-'\.
3N7K8K69W%^6.=
^MK+C[&MHBD@BTR).'TU-S"A@V Q],A9U!)\34[P04A.1LQY3)9'C
MTA[D5D^L#5:;R?UE>N+"QG3EIK=JL(.%U*:V._W^LOC$0UOX8I0*N1;/OX:^
MB"2I+
+!;/;(V6&TF]^?U"!>O1]J.
MXV+[E]ID_%TI"%GG)MM^%6V2?T2;+ ^B4+$[E=N2GZ10?=KO]\I$C;*'S
MQE[("]M8B0C&]!0V6VS\$!@(PS:8M4T<^\VTBM)JTRJDZB6]4C+8CL>BK")9
M%QTG
AE1.6[5 T2/34>F$ XL
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M2!,DTQP.BN0]](/9H=BY! O-0= O!LD8T*0*P&U$5!JKL&C2A>@@!?
--#/:4[0HJFBUA20V%=0HUK%,0(T:)@OL
MN0YF4$"9GRI'WSW16+#/N_F=2B;K2Y_0>3/2H&LZ8PQ 'TIL_* Y4 ^4LVC(
M=*-;E-E+(A13^NB,(MJ*XR7)*
:-ZN;*:Y2F%5]U
M'@J>Q%YUGK/6_ZKS=Q:SR)A0@O>A]@^7[A)!K7W4L=C64(7VXL_1?71- P9@
M&S/F,$]J<9B67CKO\65:7F!2,@NJAX/H\T'V: ^+0?"Y*/JB,,ZB4#&QI>BX
MZ+C/:BBQ
TR8"EE(=,)7
MW8<;#POK*\GIAU=P*W;,VP0/$\4TQZ,N'K@ZVS-%K09J:(ZLF_0AC;>\-'*[
M/*V"LHZ1F+N4=@\=3Q_VVJ.WO:3WD(B"B_A0Z/(7M$-M%'I,3>#V?5N;?>+W
M=\$2HPD#"E2UZ"$4L(W C <#*USG@I5TO9)IS8074Q<- RB761-\"A1'BL]3
M"PO;T(K#PBF.I6LDL)5""-!3
+1M+QI(@_T^I[*\QZDTN@30"!'4=>^[MJ$Y*D6<^L^J)@&2Y7*:?S/O>#LU
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MDFY6S.D&=F1;L[Q;8%\W929N/ML#:4?@
-R.<6G53)D&=XA3XP^V**@A1=7Q#>7M9OI,>QW9QO/Y=9M)-=3
MONHF#"Y#A,46VW3C3O1B! V1B(A>U(IV\%#""O6\:-R N8?4 P'7 Z.O1]U3
MI/BO +WIB8 U#*,+VXCY-F+^,B';V)N(Z--V[>/SVN55]PG/W'Y,&M_)$XWD
MKW%I
A-KP2XU>LL$/5[/]P,/3,JOVXK(4%%>?(%ET:68!"T!Z%S?Y034'
M:(<"TWNP2L*JJ/>1-&%W!+'XEP^@8AN[-#K&FA-=HIHV(*^\:HAKDQWI=3NA
M]!YF$GW5L,(06;"S8^PY8 3]]C I/)OYVZ/'*[6LMR.Q'8EY:R3\+B3%SGL;
M
&\/U$9OU'(E58G4TJ7RX<+!6S3@9[X4E
M6[M'-(G;H7%A;4V5S^9+$3W#Y!EVZX89E1#_,2Y?2K82\AY8L0.UCZJ:=XG;
MJAKVGBEK3E\
H;$RWD?M!OOEEBL=W;*3.MYUTW206#7\9=RZ4[B3T5WM3/U>
M'A3'1X53Z:+3N>E];:C78VTPZDH%]_2*3,1[1
)BW);EV,G-+)#_)-N)9)IEB[
M:TP:QKU1_]2Y?##Z'?7T^S=KTKD?#0>3NZ/CGGRG?77.M2]F^=O/L^YWQ31:
MWZY/6A?UNQ^Z>G=5'+N93Z/K26ER??JI:-4Z$_ZFVSMNWTSTGZ5_)M?-YDWV
MA_DE\_G\'RMOM%65:WT;Z%PQ.[8?C%/S1O\R;"G?/OV\D[A,J?/@E">]8?O0
MXTA&,I4)_:F2H5[]/U!+ P04 " ".91M='MRS/RL# #H"P $0 &=C
M=&LM,C R-C X,C
'-DM5;;
\[97>^N3/-B&E T!B$)9RVK4BI;")C+
M/<+\EO78LS_UVC
\@^P3,X^+Q_B:7'2H5RH;C
M3":3$N-C/.%B)$LN#W83["FL(IFKE:?E]+<;O4NDFY/KM6XH3Z;WY,4'=AI=
M8C:1SSCHSOIW]=_'/TX!1L/Q\^=9_R6HL=GWU]?VM]JHW7N
?3QJ)R&;
MTAU"@)'N!9,MR]27EC
*\=#N]&&
&#
M,F,F0^S"FWK9M&+&N!YJO5BIQ=C"D.BIS0W:9+K<$)S"@TX?F8/>JDU!C-MI
M
:;[)#%_ _LED?$.
M2&+#C;XNOMP$-X=XA'8-NN'+L#7H6HX#5,G,
DHX
M1L*(?K3+%=W$S>F\Q8R?Y4%#X/*(*3';9Q 6*=G#8=V8_P/8K1$9/FF"^5-P
M:-@#IJ 8?-T(-)U$31__ %!+ P04 " ".91M=U_ -]/T* !_A@ %0
M &=C=&LM,C R-C X,C=?;&%B+GAM;,V=76_CN!6&[POT/W#=FQ88Q_G #I#L
M9!<93[(P-IMD8\]LVT6QH"7&$4*3 24G]K\O*8FR1/%(2HJ2G(L9C_@>ZJ7X
MF*2^CC_]M%U3]$)$FG!V/CHZ.!PAPB(>)VQU/OHZ'U_,I[/9"*499C&FG)'S
M$>.CGW[\ZU^0_//IN_$8726$QF?H"X_&,_; ?T W>$W.T,^$$8$S+GY WS#=
MJ"W\*J%$H"E?/U.2$5E0[/@,?3SX'J/Q>$"UWPB+N?AZ/ZNJ?
8:S35K5=K@]+/\4X9]HPI[.U%]+G!(D#Q=+S[9I
M
#3YYZ_7\^B1K/$X8>JP162DHU0MMKBCT]/325ZJ
MI2WE=BFHWL?)1-NI:I:E28>^YB1-SM+
N]N$*A0_QMKV5AM&A\=
MCT^.#K9I/-('/S^"@E-R3QY0WLRS;/
-NLJ@B6NS=T0D/+YD[W-M1GNR
M+[\[(OL?&E"/=]Z$!<\P?9?Y>J1SVS?D?4=\'^?^2,MAGKSO2-
^W&E:N.U_-2P2+:9G,!(K$VJ*CI&X'P/^<10UEW5SJ-&O52-YERTVZYF
MQKS.E$0'*_XRB4DBZS[^J#Z,U8>\V?(_?TZY7 A<+--,X"C3->7-.!]9RB>F
M):6\$-H7%E%/XTK%).)R:GK.QK0XC$7X@^!KZV[+5G-+X9]T6<47AT7N C#:
MD F2\HV(R)MZI>X6.DJEHS65"K6B(FS\=3[Z,=>@/[3J/Y\F^UH<=+1< FW6
MA&4+6:.E!
:=;3+;ZOJ8)"X&V
M,9B$FM;3P'Y/5HF:6I0%=7Y+U,:.80S0NQ[Z.VV;
L1-!=[U0
MM)2NN0"LFF@8LJ#HL'L# :GD?AE9",S21 U@O9"TI
TP(9-7MK*H(@![8',Y!&H# D'F\L7M3J7
MRZ2!C:WI?<+3LMW%3R4.%B'3X4"*\C"DXCR15+L-T<-02^F:'L"JR8TA"XH8
MNS>0E4*.
E
M'
:T@\L+:MV5"I9@*"8
MWOHP47HOD$PW0C1
,73#'3)LB3;
MJ
VTUF '% Z'0[! B20:@9Y1.D&8NX
M>.:UQQVF?",'P-V4Q_ *I2?*+52#FM!$JS,D(,"&^ 0P:X1^*)Y)05R]QI-7
M@%0-7HB[B&-YH-+RG^N$D2.P_5:M6[HZ[#:9L@@#(@EV!_!3*C_H#TC%H%L6
M"C3';VCJL7]HCH="
"OMH>S0:479-I6K<#L9>'ATO+6!XL*4.L9%>(3DWQA=2ON!'])
M6 0OF2&Y%V TU9J#&UXZ-@-]O%3+8AUG->QIEB4]WY)M,S/*-,T:1]B"DUX
MD#2-]0XNA=HG$G<\S3#]=_+<>2)N%WO!PVK8"DE#&1XJ-GM]P!0Q2 ;Y.+$N
M<54W-*RODAGE[EX!MMC:OP)<*PP" INC]BO Q=630N2ZFQ6C@F!@1&@6.^MD
MBZFJCVME871QVU"KA_/OM=3X^"*K["[T[I$S^ &!ML153T/F=&^;Y4'T.&#*
M[/5
M=TTYJF=;GCWOQ=))G<\Y2O
MUQM6WN6Q/3<(Z%SU
-641"]W^7,)*'4HJ;8,19S3I,HR1*V^E6>?(H$
MVUIE$[D" C:H:6@K@D !M&5RL!
LDID'W*JG(%08=%S8%%$@0*L"^3AAN.
M2BDJM#ZR4S7,6IICE+L"P&I+=WVC,(A.MSEJ??D;?>UIR+_<1H_2% %>2+#+
M7 _]-I/F\%_7!(% A['624DI15KKXX6$_92UZE\$K+PM E8]BX!5B(N U=!%
MP,K;(D#OMD@1(L>EVR5-5AA(3MBI=@U%AV63#XLT*%1@?^"8486@?8SKC)9Y
MBC.5GE^L\_U?R0^65@(Z9SDMNVQ622UMHB 8Z7+62FM9))VKB9%2N^9B$R<9
MB0LS5PG#+$HPK=(CVJZ(]X
4_L+X*YL3G')&XN):BNU.4;?>[1,S/;:;#\T XB!P&N(0>'1&!8V?
M5!328>65,"\D?>-TPS(L\G?)A6UD G1NR0%L-HDQ1 &18G<&$%*)4:'V\X)V
MD3VB6F05OSL$-A"2.WY=N].T\=:V51L0,YT&H7>XRYP?^[5Q$>7I%
T++9SQU22@/"P^>K((".0UGIA8;[&E'[>I DC*3P1&2JW+%@M
M-EEH2 )BP>8+8"&7(JWUPL+EFHB5G-Y^%OPU>RSSLX)M ]1NV>BTW&3$*@V(
ME2Y_ #,Z!!4Q.J6N'WBV^X3B199%N*46J6-L0+,&,RU=2,! YEJT4!*IZRTW
M/$,+CKZF!&6/!%V6/T-7SP1?U./KET:B2+T04:S*68R%#:$NL?-?'0$-MWY[
MI*4, J1>>_#OD%012(
B%2DSVQ&]>3V\!*O(7*\,K88-!;&-440C("VH&5Q_;<"_.3.
MVRQI$EU1CN&K+ V-XXQY;7M&LKR](" "VJZ@%'FY$.5*+_W_&;,GL7G.HMV=
MX!$AZBFKM!JM^JZ_#8QVR\R;FM2D:5!H0)R]Q2] X+X*5*OC0VW&\GDQ3STT
MKK*Y\>AI_HCE ;S=9*F:0:4Q^"IX9Y#CVPL#&F#<9.B(" B] 3:A&PYY),I#
M/Z B&-6B/9V?I?LL@"3^O+LG#T2H]PX69)M]ECMZZCC#&!#K^NQM<'/,D[G>
MP" @?*M;Z%0O1?4*T%(](U96@?Y0E:"\%MOOE]
)/]:XI3(+?\%
M4$L#!!0 ( (YE&UTR+)596P< -A7 5 9V-T:RTR,#(V,#@R-U]P
M
&ULS9S?<]HX$,??;^;^!Q_W3 CDKFUH
GK8B*
M6"9,S"Y;7\?MJ_%@-&I%VA"1$"X%O6P)V7KWUZ^_1/;GXK=V.QHRRI-^]$'&
M[9&8RK?1%Y+2?O21"JJ(D>IM](WPS!V10\:IB@8R77!JJ/VB:+@?O3KYDT3M
M-J#:;U0D4GV]'VVKG1NST/U.9[E
J36*:P"L>&F$QO:SM=G6Y^
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M]F-AN7&E=(;+>*]][J(@U3Z#LD?GK#6-3V;RJ9-0UG%
?T_K,V!2:
MF !Y=C& 5JK!(OJ!ZEBQA>-2 W;/$LBWA\JW0EO#F,MSYY[.F//7N>(NN=0=
M#(\+GB) \&>8(T50+5($KH3("+^G"ZEJP.]; GG_@
#XH(S1P?"/!C:R#Q5Z@W'AZ-2,C'<\JYR^*( /7R*GL@
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M%?.80O&BI']!>0VC'DO.8F:8F'VV=XB*$5[-N
M=N?KN-Q> W4[G?I&WI ]E#A*KE
$:9(RLH:Y24SR>J8;9?Y(,B;KO>>)U.)/=O#ZDTA!)&2? "
MTAJ&O.='-=X#$RA8E,RN4@[2F'"]BN=$S*A_]4*U)10P2J87$H
<<\)A"
MD2/.'7KDX:R]+!8U;Z\]Q2L[0L1]):#@$2<1PV*1UJ<9ZGQF3_0#,63C88B_
MKP24/^*$8E@LVOIY-; 7GID,SYD?&$)I(RZ%K92& GF<$L[?9YH)JH-CRX$A
M%#+BFM=*:2B0KU.J9G90^ZCDTLPW>SM#L#T%H- 15[8&I>+ 7_W<1U[L?PN2
MK[ &OYT $;M7)-9K-^+8+:0HKN0B(
[]4^[,
MR.9MH44/]:6@44!)5Z&B<:ZM.SOY@Y?6/3LH;\3$M$H8SIZI;,)9/.22!._+
M]\R@?!&ST I9*'C?$_&HLH6)UW=*QI2ZZ1.]/=L "1&P FA($//39Z' >5P@
MT]1M)I+QXWAN1>O;S.0O,+7^!1\:!,M!0X.YB1,@'.DN2/_
X2X1( -.; +
M " 2L0 !F;W)M."UK+FAT;5!+ 0(4 Q0 ( (YE&UT>W+,_*P,
M .@+ 1 " 34C !G8W1K+3(P,C8P.#(W+GAS9%!+ 0(4
M Q0 ( (YE&UW7\ WT_0H '^& 5 " 8\F !G8W1K
M+3(P,C8P.#(W7VQA8BYX;6Q02P$"% ,4 " ".91M=,BR565L' #85P
M%0 @ &_,0 9V-T:RTR,#(V,#@R-U]P
&UL4$L%!@
0 % 4 -@$ $TY $!
end
XML
15
form8-k_htm.xml
IDEA: XBRL DOCUMENT
0001506983
2026-08-27
2026-08-27
false
0001506983
8-K
2026-08-27
GLUCOTRACK, INC.
DE
001-41141
98-0668934
301 Rte. 17 North
Ste. 800
Rutherford
NJ
07070
(201)
842-7715
false
false
false
false
Common Stock, par value $0.001 per share
GCTK
NASDAQ
false